The research team — led by Erping Long and Haotian Lin of Guangzhou, China-based Sun Yat-sen University — developed CC-Cruiser, an AI platform that uses deep learning to risk stratify populations for screening, diagnose patients for the disease and provide clinical support to ophthalmologists making treatment decisions.
The researchers launched a multihospital clinical trial to validate the utility of CC-Cruiser and are working to compare the AI platform’s performance with trained ophthalmologists. The team wrote that the trial will “explore the management of rare diseases and the cloud-based AI platform for providing medical suggestions for non-specialized hospitals.”
“The collaborative platform could be extended to the management of other rare diseases, and should be validated in different clinical scenarios,” they wrote.
More articles on health IT:
‘Watson for Oncology’ debuts in US
Accenture forecast: ‘AI is the new UI’
Penn Medicine uses data analytics to drive cancer-focused urgent care
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
